Genmab Price to Sales Ratio 2019-2021 | GMAB

Historical PS ratio values for Genmab (GMAB) over the last 10 years. The current P/S ratio for Genmab as of December 07, 2021 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Genmab P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2021-12-06 36.92 18.97
2021-09-30 43.70 $1.95 22.46
2021-06-30 40.83 $1.80 22.66
2021-03-31 32.83 $2.54 12.92
2020-12-31 40.66 $2.35 17.28
2020-09-30 36.61 $2.53 14.47
2020-06-30 33.89 $2.36 14.37
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $24.258B $1.549B
Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $126.142B 7.97
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.170B 20.61
Biohaven Pharmaceutical Holding (BHVN) United States $6.566B 0.00
Arcus Biosciences (RCUS) United States $3.079B 0.00
Emergent Biosolutions (EBS) United States $2.259B 8.12
Myovant Sciences (MYOV) United Kingdom $1.408B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.382B 0.00
Zymeworks (ZYME) Canada $0.848B 0.00
SQZ Biotechnologies (SQZ) United States $0.318B 0.00
Ambrx Biopharma (AMAM) United States $0.306B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.90